Table 2.

Comorbidities of COVID-19 survivors, primary Raynaud's phenomenon patients and control subjects at the time of nailfold videocapillaroscopy.

		Controls (N = 30)		Primary Raynaud's phenomenon (N = 31)		Mild/moderate COVID-19 (N = 34)		Severe COVID-19 (N = 27)
Arterial Hypertension	No	21	(70.0%)	19	(61.3%)	20	(58.8%)	13	(48.1%)
	Yes	9	(30.0%)	12	(38.7%)	14	(41.2%)	14	(51.9%)
Type II diabetes	No	29	(96.7%)	29	(93.5%)	32	(94.1%)	23	(85.2%)
	Yes	1	(3.3%)	2	(6.5%)	2	(5.9%)	4	(14.8%)
Chronic atrial fibrillation	No	28	(93.3%)	27	(87.1%)	32	(94.1%)	26	(96.3%)
	Yes	2	(6.7%)	4	(12.9%)	2	(5.9%)	1	(3.7%)
CHD	No	29	(96.7%)	31	(100%)	33	(97.1%)	25	(92.6%)
	Yes	1	(3.3%)	0	(0.0%)	1	(2.9%)	2	(7.4%)
COPD	No	27	(90.0%)	30	(96.8%)	33	(97.1%)	23	(85.2%)
	Yes	3	(10.0%)	1	(3.2%)	1	(2.9%)	4	(14.8%)
Asthma	No	25	(83.3%)	29	(93.5%)	26	(76.5%)	24	(88.9%)
	Yes	5	(16.7%)	2	(6.5%)	8	(23.5%)	3	(11.1%)
Neurological disorders	No	27	(90.0%)	29	(93.5%)	32	(94.1%)	27	(100%)
	Yes	3	(10.0%)	2	(6.5%)	2	(5.9%)	0	(0.0%)
Dyslipidemia	No	27	(90.0%)	26	(83.9%)	31	(91.2%)	24	(88.9%)
	Yes	3	(10.0%)	5	(16.1%)	3	(8.8%)	3	(11.1%)
Cancer	No	28	(93.3%)	28	(90.3%)	33	(97.1%)	24	(88.9%)
	Yes	2	(6.7%)	3	(9.7%)	1	(2.9%)	3	(11.1%)
Chronic arthritis	No	30	(100%)	31	(100%)	28	(82.4%)	26	(96.3%)
	Yes	0	(0.0%)	0	(0.0%)	6	(17.6%)	1	(3.7%)
Thyroid disease	No	26	(86.7%)	24	(77.4%)	27	(79.4%)	26	(96.3%)
	Yes	4	(13.3%)	7	(22.6%)	7	(20.6%)	1	(3.7%)

Results are express with frequency and percentage, as appropriate. CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease.